



Iclusig

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date:** _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____ **NPI#:** _____
Specialty: _____ **Physician Office Fax:** _____
Physician Office Telephone: _____
Request Initiated For: _____

- What is the diagnosis?
 Chronic myeloid leukemia (CML)
 Acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL)
 Myeloid neoplasm with eosinophilia
 Lymphoid neoplasm with eosinophilia
 Other _____
- What is the ICD-10 code? _____
If diagnosis is myeloid or lymphoid neoplasm with eosinophilia, skip to #4
- Was the diagnosis confirmed by detection of Philadelphia (Ph) chromosome or BCR-ABL gene by cytogenetic (conventional or FISH) and/or molecular (PCR) testing? ***ACTION REQUIRED: If Yes, attach results of cytogenetic and/or molecular test results.*** Yes No
- Is the patient currently receiving the requested medication? Yes No *If No, skip to diagnosis section*
- Is there evidence of unacceptable toxicity or disease progression on the current regimen?
 Yes No *No further questions*

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Chronic Myeloid Leukemia (CML)

- Does the patient have T315I-positive chronic myeloid leukemia (CML)? ***ACTION REQUIRED: If Yes, attach T315I mutation test results and no further questions.***
 Yes No Unknown or testing has not been completed
- What phase is the patient's disease?
 Chronic phase
 Accelerated phase, *skip to #9*
 Blast phase, *skip to #9*

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Iclusig SGM - 2/2021.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081
Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com

8. Has the patient experienced resistance or intolerance to at least two prior kinase inhibitors (e.g., imatinib [Gleevec®], nilotinib [Tasigna®], dasatinib [Sprycel®], bosutinib [Bosulif®])?
 Yes No *No further questions*
9. Is treatment with ANY other kinase inhibitor (e.g., bosutinib [Bosulif®], dasatinib [Sprycel®], imatinib [Gleevec®], nilotinib [Tasigna®]) indicated for this patient? Yes No

Section B: Myeloid Neoplasm with Eosinophilia and Lymphoid Neoplasm with Eosinophilia

10. Does the disease have ABL1 or FGFR1 rearrangement? ***ACTION REQUIRED: If Yes, attach results of testing or analysis confirming ABL1 or FGFR1 rearrangement.*** Yes No Unknown
11. Is the disease in the chronic phase or blast phase?
 Yes, chronic phase
 Yes, blast phase
 None of the above

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Iclusig SGM - 2/2021.

CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081

Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com